Joyce O’Shaughnessy

机构：Texas Oncology, Baylor University Medical Center · ORCID：0000-0001-6764-2807

发表论文 661 篇 · 总被引 23123 次 · h-index 70

代表论文

• Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial. (2025 · Journal of Clinical Oncology · 被引 8)
• Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion (2025 · npj Breast Cancer · 被引 6)
• US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan (2025 · Supportive Care in Cancer · 被引 6)
• Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women With Low-Risk Ductal Carcinoma In Situ After Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-Year Ipsilateral Breast Recurrence Rates (2025 · International Journal of Radiation Oncology*Biology*Physics · 被引 5)
• Abstract PS7-02: First-in-human results of STX-478, a mutant-selective PI3K alpha inhibitor, in HR+ breast cancer and advanced solid tumor patients (2025 · Clinical Cancer Research · 被引 4)
• ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study. (2025 · Journal of Clinical Oncology · 被引 4)